Sign In
Buy DXCM
$72.77
-0.680 (-0.93%)
At Close: Jun 03, 2026
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
12:24pm, Tuesday, 30'th Sep 2025
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their f
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
10:00am, Sunday, 28'th Sep 2025
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
10:51am, Wednesday, 24'th Sep 2025
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). Such investors are advised
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
10:00am, Tuesday, 23'rd Sep 2025
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).
What Moved Markets This Week
06:45am, Saturday, 20'th Sep 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
02:07pm, Friday, 19'th Sep 2025
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fidu
Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA
10:57am, Thursday, 18'th Sep 2025
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. DXCM, citing that the company sold the "adulterated" device.
VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
10:27am, Sunday, 14'th Sep 2025
When it comes to identifying target stocks for investment, compelling prospects may include companies that are undervalued and, simultaneously, expected to appreciate in the future.
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
01:37pm, Thursday, 11'th Sep 2025
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fi
DexCom, Inc. (DXCM) Presents At Baird Global Healthcare Conference 2025 Transcript
04:23pm, Wednesday, 10'th Sep 2025
DexCom, Inc. (NASDAQ:DXCM ) Baird Global Healthcare Conference 2025 September 10, 2025 2:00 PM EDT Company Participants Sean Christensen - Vice President of Finance and Investor Relations Conference C
Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day
08:30am, Wednesday, 10'th Sep 2025
SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada i
DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
04:53pm, Wednesday, 03'rd Sep 2025
DexCom, Inc. (NASDAQ:DXCM ) 2025 Wells Fargo Healthcare Conference September 3, 2025 2:15 PM EDT Company Participants Jacob Leach - President & COO Jereme Sylvain - Executive VP, CFO & Chief Accountin
Investing in the Age of Longevity: Silver Economy Stocks in Focus
01:16pm, Monday, 01'st Sep 2025
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?
12:31pm, Friday, 29'th Aug 2025
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock?
